COPN.SW Stock Risk & Deep Value Analysis
COPN.SW
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About COPN.SW Stock
We analyzed COPN.SW using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran COPN.SW through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is COPN.SW Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for COPN.SW?
- ⚠
Lower-than-expected Lumeblue sales growth or market adoption.
- ⚠
Negative clinical trial results for pipeline candidates.
- ⚠
Increased competitive pressure or new market entrants with superior technology.
- ⚠
Regulatory hurdles or delays for new approvals.
Unlock COPN.SW Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does COPN.SW (COPN.SW) Do?
Market Cap
$1.46B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
332
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Visit COPN.SW WebsiteIs COPN.SW Stock Undervalued?
Unlock the full AI analysis for COPN.SW
Get the complete DVR score, risk analysis, and more
Is COPN.SW Financially Healthy?
P/E Ratio
27.45
Does COPN.SW Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat primarily stems from its MMX technology platform and the associated intellectual property (patents), offering a unique drug delivery mechanism. This allows for improved efficacy and safety profiles, creating a competitive barrier. As Lumeblue gains market share and other MMX products advance, the moat strengthens. Durability is estimated at 10-15 years, aligned with patent lifecycles and the time it takes for competitors to replicate or innovate around the technology.
Moat Erosion Risks
- •Patent expiry or successful challenges to intellectual property.
- •Development of superior, non-MMX based technologies by competitors.
- •Failure of pipeline products to achieve market success, limiting platform value.
COPN.SW Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive COPN.SW Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated May 2026) - Focus on Lumeblue sales metrics.
- •Updates on Lumeblue commercialization milestones and market adoption rates in initial territories.
Medium-Term (6-18 months)
- •Potential expansion of Lumeblue into new European markets or additional GI segments.
- •Clinical trial updates or initiation of Phase 3 studies for other MMX pipeline candidates.
- •Strategic partnership announcements for pipeline assets or market access.
Long-Term (18+ months)
- •Lumeblue establishing significant market leadership in GI diagnostics.
- •Successful development and commercialization of multiple drugs from the MMX platform.
- •Potential acquisition interest from larger pharmaceutical companies for its technology platform or successful assets.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for COPN.SW?
- ✓
Acceleration in Lumeblue's sales figures and market share gains.
- ✓
Positive clinical trial readouts for late-stage pipeline assets.
- ✓
Sustained healthy cash flow generation and prudent capital allocation for R&D.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for COPN.SW (COPN.SW) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
